India's cheap weight-loss drugs could reshape global obesity fight
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"Prices are expected to fall sharply."
— Sheetal Sapale , Other
"It is great that these will become cheaper so that more of the diabetic and obese Indian population can access them."
— Muffazal Lakdawala , Other
Key People
Locations
All Coverage
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Similar Stories
Related coverage based on topic and tags
New global guidelines warn against obesity drugs for children under 10
Care should focus on healthy eating and exercise, not medicines such as weight-loss injections, says the World Health Organization
October 7, 2026 at 08:07 AMWHO endorses lifestyle changes over GLP-1 drugs in child obesity fight - Reuters
WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight Reuters
October 7, 2026 at 07:39 AMReliance sues India's food regulator over 'energy drink' label ban - Reuters
Reliance sues India's food regulator over 'energy drink' label ban Reuters
October 6, 2026 at 04:18 AMTeva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AMIndia joins global rate-tightening wave with first hike in nearly 4 years - Reuters
India joins global rate-tightening wave with first hike in nearly 4 years Reuters
October 7, 2026 at 04:33 AMHalozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme wins court order to block Merck's injected Keytruda in select European markets Reuters
October 7, 2026 at 05:03 PM